The move means that Vanessa Researchʼs Hungarian division will occupy a much larger space than before, covering the full 8th floor of the office building. The company says that the move supports VRI Hungaryʼs continued expansion.
“This is an exciting step forward for VRI – Budapest is quickly becoming a hub for start-ups like us, and it will greatly benefit the company to draw from the cityʼs highly-educated talent pool as we scale our operations,” commented Bence Krümmer, managing director at VRI Hungary.
According to the press release ,
VRI considers its European presence critical as the company makes its way towards Phase II clinical trials of Shylicine, the first-ever drug developed for treatment of microvillus inclusion disease, a rare inherited intestinal disorder.
In addition to Budapest, Vanessa Research operates from its offices in Hamden, Connecticut; Farmington, Connecticut; London; and Navarre, Spain.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
